A typical SAP-pathway psilocybin-assisted therapy program in Canada costs CAD $2,500 to $6,500 out-of-pocket in 2026, including preparation sessions, the dosing day with two therapists, and integration sessions. The drug cost — synthetic psilocybin from Canadian licensed producers like Filament Health — is often provided at no charge to SAP-approved patients, which materially reduces patient cost relative to international markets. Quebec is the only Canadian province with established public funding (Drs. Houman Farzin and Jean-François Stephan billed RAMQ in December 2022 for an SAP-approved patient with end-of-life distress). Veterans Affairs Canada does not currently cover psilocybin-assisted therapy — a meaningful contrast to ketamine, which VAC does cover for service-related conditions. Private insurance generally does not cover psilocybin (Schedule III, no Health Canada approved indication), though therapy fees may be partially covered as standard psychotherapy when delivered by a covered profession. This article walks through the cost components honestly, the insurance reality, and how ATMA CENA fits financially.
Key takeaways
- Typical out-of-pocket cost: CAD $2,500–$6,500 per full program (preparation + dosing day + integration).
- Drug cost: often $0 — Filament Health provides synthetic psilocybin to SAP-approved Canadian patients at no charge in many cases.
- Quebec RAMQ is the only province with a public-funding precedent (Farzin / Stephan, December 2022 — first publicly funded psychedelic therapy in Canada).
- Veterans Affairs Canada does NOT cover psilocybin — different from ketamine.
- Private insurance: drug not covered; therapy fees may be partially covered as standard psychotherapy.
- International comparison: Australia ~AUD $15,000–$30,000 per program; Oregon ~USD $1,500–$3,500 per session — Canadian SAP-pathway pricing is meaningfully lower because of Filament's no-charge drug supply.
Where the money goes — cost components
A typical Canadian SAP-pathway psilocybin program includes:
| Component | Cost (CAD) | Notes |
|---|---|---|
| Preparation sessions (2–3 sessions) | $300–$900 total | Standard Canadian psychotherapy rates ($150–$300/session) |
| Dosing session (one 6–8 hour session with 2 therapists, clinical setting) | $2,000–$4,500 | Largest single cost component; reflects therapist time + facility + monitoring |
| Integration sessions (2–4 sessions) | $300–$1,200 total | Standard psychotherapy rates |
| Drug cost (synthetic psilocybin, e.g., Filament PEX010 25mg) | Often $0 | Filament Health provides drug at no charge to many SAP-approved patients |
| Intake / SAP application coordination (some clinics) | $0–$300 | Varies; not all clinics charge |
| Total typical program | CAD $2,500–$6,500 | Varies by provider, indication, single vs two-dose protocol |
The two largest variables: how many preparation and integration sessions the clinical model uses, and whether one or two dosing sessions are planned. Most published trials and SAP programs use a single 25 mg dosing session; some protocols (Bogenschutz 2022 AUD; some end-of-life programs) use two doses 1–4 weeks apart, which roughly doubles the dosing-session cost.
For ATMA CENA-pathway pricing context, see ATMA CENA KAT pricing tiers below.
Why Canadian psilocybin therapy is cheaper than Australian or Oregonian — Filament's role
Filament Health is the first DEA-licensed Canadian producer of natural psilocybin. Filament has consistently provided their PEX010 capsule (25 mg synthetic psilocybin) to SAP-approved Canadian patients at no charge in many cases — meaningfully reducing patient out-of-pocket cost for the drug component. Other Canadian licensed suppliers (Optimi Health, Psyence Group) supply paid-for synthetic psilocybin through varied commercial arrangements.
International comparison:
- Australia (TGA-authorized psilocybin for TRD, July 2023): typical patient cost AUD $15,000–$30,000 per program. Drug cost is borne by patient.
- Oregon (Measure 109 licensed psilocybin services, 2023): typical session cost USD $1,500–$3,500. State-licensed facilitator model, no medical insurance coverage.
- Switzerland (Section 8 compassionate access): limited; no standardized commercial pathway.
Canadian SAP pathway is meaningfully cheaper than Australian primarily because of Filament's drug-supply model and because Canadian SAP-pathway programs have not commercialized at the Australian regulatory tier. Canadian and Oregon prices are comparable per session, but Canadian programs typically include preparation and integration in the bundled price while Oregon's licensed facilitator model is session-only.
Insurance reality — honest framing
Public coverage
Quebec RAMQ is the only Canadian province with a public-funding precedent. Drs. Houman Farzin (palliative psychiatrist, Jewish General Hospital, McGill) and Jean-François Stephan billed RAMQ for SAP-approved psilocybin-assisted therapy delivered to a patient with end-of-life distress in December 2022. RAMQ subsequently modified billing codes to permit further public claims for SAP-approved Quebec patients. The pathway requires:
- SAP authorization in place
- Quebec resident
- Eligible indication (typically end-of-life distress)
- Quebec-based prescribing physician willing to apply for SAP and bill RAMQ
This is a real public pathway but capacity-limited and dependent on physician engagement.
Other provinces: provincial drug plans do not list psilocybin. There is no equivalent public-funding pathway elsewhere in Canada.
Veterans Affairs Canada — does NOT cover psilocybin
This is a meaningful difference from ketamine. VAC does not currently cover psilocybin-assisted therapy for veterans, citing insufficient evidence in the veteran-specific population. By contrast, VAC does cover ketamine (IV, oral, intranasal, compounded cream) for service-related TRD or chronic pain on a case-by-case basis — see Ketamine Therapy for PTSD.
For Canadian veterans pursuing psychedelic-assisted therapy where coverage matters:
- Ketamine pathway: VAC-covered case-by-case for service-related TRD or chronic pain.
- MDMA-assisted therapy: SAP-pathway only in Canada; VAC covers case-by-case for service-related PTSD where SAP-approved.
- Psilocybin pathway: not currently VAC-covered.
Alberta Blue Cross PAT (March 2024)
Alberta Blue Cross became the first Canadian insurer to cover psychedelic-assisted therapy in March 2024. The covered scope at announcement was ketamine-assisted therapy; psilocybin coverage was framed as future potential once formally legalized for clinical use in Canada. Confirm current scope with Alberta Blue Cross directly.
Private extended-health insurance
The drug (psilocybin itself): essentially never covered by private insurance. Schedule III status with no approved Canadian indication does not align with standard formulary inclusion.
Therapy fees (preparation and integration psychotherapy): may be partially covered as standard psychotherapy when delivered by a registered profession (Registered Psychotherapist, Registered Psychologist, Registered Clinical Counsellor, Registered Social Worker depending on province). Some clinics provide receipts billable through extended-health benefits.
The realistic patient picture: drug cost is the variable saved by Filament's no-charge supply; therapy fees may be partially recoverable through extended-health coverage; the dosing-day infrastructure cost remains out-of-pocket for most patients.
ATMA CENA's pricing context
ATMA CENA's published KAT pricing tiers — applicable to ketamine — are:
- KAT Psychedelic Pathway: from CAD $1,585 + $795/additional session
- KAT Psycholytic Pathway: from CAD $1,530 + $740/additional session
- Customized programs: CAD $2,325–$6,930 (2–8 sessions)
- Non-refundable deposit: CAD $300
Whether these tiers apply to SAP-pathway psilocybin work — particularly given the longer dosing session (6–8 hours vs ~90–120 min for ketamine) and the SAP-application medical coordination — should be confirmed at intake. The structural shape of psilocybin-pathway pricing is likely similar but with adjustments for session length and SAP coordination overhead.
For the broader Canadian psychedelic-assisted therapy pricing context, see Ketamine Therapy Cost in Canada.
Comparison: psilocybin SAP pathway vs ketamine pathway costs in Canada
| Psilocybin (SAP pathway) | Ketamine (off-label or Spravato) | |
|---|---|---|
| Per-program cost | CAD $2,500–$6,500 | CAD $1,530–$6,930 (ATMA CENA KAT pricing) |
| Drug cost | Often $0 (Filament SAP supply) | Generic ketamine bundled in clinical fees; Spravato ~$800–$900/session |
| Insurance | Quebec RAMQ only public pathway; VAC does NOT cover | VAC covers ketamine case-by-case; WSIB Ontario formularies; Alberta Blue Cross PAT covers ketamine; Spravato most likely privately covered |
| Sessions per program | Typically 1–2 dosing sessions + 4–7 prep/integration | 4–8 IV sessions or 12-session Spravato induction + integration |
| Dosing session length | 6–8 hours | 90–120 min IV; ~150–180 min Spravato |
| Public coverage | Quebec only | Edmonton public Misericordia/Grey Nuns IV ketamine for ultra-resistant TRD (AHCIP) |
Honest takeaway: psilocybin SAP-pathway costs and ketamine costs are in similar ranges in Canada, but the insurance pathways and access patterns differ materially. Patients with private benefits supporting Spravato or VAC-eligible patients with service-connected conditions will often find ketamine the more financially accessible pathway. Patients in Quebec with end-of-life distress may have access to public funding via RAMQ that does not exist elsewhere.
For the cross-treatment comparison, see Ketamine vs Psilocybin Therapy.
Frequently asked questions
How much does psilocybin therapy cost in Canada? Typically CAD $2,500–$6,500 per full program out-of-pocket, including preparation, dosing day, and integration sessions. Drug cost is often $0 because Filament Health supplies SAP-approved patients at no charge in many cases.
Why is the drug often free? Filament Health, a Canadian licensed producer, has consistently provided synthetic psilocybin to SAP-approved patients at no charge as a public-good and clinical-research-development model. Not every SAP-approved patient receives the no-charge supply, but it is common.
Does Quebec really cover psilocybin therapy publicly? Yes — Drs. Farzin and Stephan billed RAMQ for SAP-approved psilocybin-assisted therapy in December 2022, the first publicly funded psychedelic therapy in Canada. RAMQ subsequently modified billing codes for further claims. The pathway is real but requires SAP authorization, Quebec residency, eligible indication, and physician willingness.
Does VAC cover psilocybin therapy for veterans? No. This is a meaningful contrast to ketamine, which VAC does cover for service-related TRD or chronic pain. VAC has not extended coverage to psilocybin-assisted therapy in 2026.
Does private insurance cover psilocybin therapy? The drug itself is generally not covered. Therapy fees (preparation and integration psychotherapy) may be partially covered as standard psychotherapy when delivered by a registered covered profession.
How does this compare to ketamine therapy cost? Per-program costs are in similar ranges (CAD $1,500–$7,000). The insurance pathways differ: VAC and private prior-auth more often support ketamine and Spravato; psilocybin SAP-pathway is essentially out-of-pocket outside Quebec.
How does Canadian psilocybin therapy cost compare internationally? Meaningfully cheaper than Australia (AUD $15,000–$30,000/program) primarily because of Filament's drug-supply model. Comparable per session to Oregon (USD $1,500–$3,500/session), with Canadian programs typically including preparation and integration in the bundled price.
Does ATMA CENA offer psilocybin pricing comparable to its ketamine pricing tiers? ATMA CENA's published KAT pricing applies to ketamine. Psilocybin-pathway pricing has the same structural shape (preparation + dosing + integration) but the longer dosing session and SAP-coordination overhead may shift the total. Confirm at intake.
Is Alberta Blue Cross PAT coverage applicable to psilocybin? The March 2024 launch covered ketamine. Psilocybin coverage was framed as future potential once formally legalized for clinical use. Confirm current scope with Alberta Blue Cross directly.
Where can I find a willing prescribing physician to keep cost lower? TheraPsil maintains a directory of trained Canadian clinicians. Some clinics offer integrated SAP-application coordination, preparation, dosing, and integration in a bundled package. The ATMA CENA intake call can orient you to appropriate resources.
Sources
- ATMA CENA — Psychedelic-Assisted Therapy: https://psychedelic.healthcare/
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- TheraPsil — Understanding Costs: https://therapsil.ca/understanding-costs/
- TheraPsil — Quebec first province to cover psilocybin therapy: https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/
- Filament Health: https://filament.health/
- Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
- Alberta Blue Cross — psychedelic-assisted therapy coverage announcement (March 2024): https://www.atmajourney.com/alberta-blue-cross-covers-pat/
- PsyCan — Sharp decline in SAP approvals: https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
- Optimi Health: https://www.optimihealth.ca/
Related articles in this cluster
- Psilocybin Therapy in Canada
- What Is Psilocybin Therapy?
- How to Access Psilocybin Therapy in Canada (SAP)
- Psilocybin Therapy for End-of-Life Distress
- Ketamine vs Psilocybin Therapy
- Ketamine Therapy Cost in Canada — modality cost comparison
- Insurance Coverage for Ketamine Therapy — ketamine-side coverage detail
Last updated: 2026-05-06